Word count for text:NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Objectives: The role of combined presence of vitamin D deficiency and other risk factors of stroke in ischemic cerebrovascular accident (CVA) development in Iranian adults has been unclear, so far. The association of vitamin D status at admission with ischemic CVA severity and outcome in this community is not yet well elucidated. This study aimed to clarify these ambiguities. Methods: In a cross-sectional study 104 hospitalized ischemic CVA patients and 104 healthy controls participated. The serum level of 25 (OH) D3 and baseline biochemical parameters were measured in ischemic patients within the first 24 h of admission, as well as healthy controls. The severity of CVA and clinical outcome were assessed using National Institutes Health Stroke Scale and Modified Rankin Scale, respectively. Data were analyzed using the Chisquare test, independent t-test, and multiple logistic regression. Results: There was a significant difference between patients and controls regarding the presence of vitamin D3 deficiency, hypertension, smoking, and baseline level of LDL and FBS. Vitamin D3 deficiency boosted the risk of ischemic in males and those having family history of CVA. A low serum level of 25 (OH) D3 was associated with more severity and poor outcome of CVA. The CVA severity, vitamin D3 deficiency, and hypertension were predictors of poor outcome. Conclusions: The study highlights the increased risk of ischemia in Iranians by cooccurrence of vitamin D3 deficiency and other risk factors of CVA. Clinical significance of vitamin D3 deficiency control may be suggested in those at risk of CVA and functional poor outcomes.
Background: Tinnitus is defined as the perception of sound in the ear or head in the absence of an external stimulus for which we have no definite treatment. Neurotec is a medication of herbal origin with IFDA approval. Previous studies showed the neuroprotective effect of Neurotec. In this study, we evaluated the effectiveness of Neurotec in improving tinnitus symptoms.
Methods: This double-blind randomized clinical trial was performed on patients with tinnitus. Patients received Neurotec 100 mg capsules (BID) or placebo for three months. Pure tone audiometry (PTA) was measured at 0.5, 1, 2, 4, and 6 kHz frequencies. Using a Tinnitus Handicap Inventory (THI) questionnaire, tinnitus loudness, daily annoyance, daily life or sleep disturbance, daily perception, and mood alteration were evaluated.
Results: Finally, 103 (69 male and 34 female) patients with a mean age of 51.33 13.91 years were analyzed. There was no significant difference between the intervention (n=53) and the control group (n=50) regarding baseline symptoms before and one month after the intervention (P>0.05). While they were significantly different three months after the intervention (P<0.05). The mean pure-tone air and bone conduction were not significantly different between the control and the intervention group before and three months after the intervention at 0.5,1,2 and 4 kHz (P>0.05). The mean pure-tone air conduction was not significantly different between the two groups before and three months after the intervention at 6 kHz (P>0.05).
Conclusion: A three-month treatment with Neurotec Capsules beside patient education can effectively control symptoms of patients with tinnitus.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.